HS-10506 in Healthy Subjects

Phase 1, randomised, double-blind trial in Insomnia comparing HS-10506 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events (AEs), serious adverse events (SAEs) and adverse events leading to discontinuation, Number of participants with clinically significant change from baseline in vital signs and 3 more. Status: unknown.